Neurocords

growth-positive

Orgenesis Inc., a global biotech company, announced the acquisition of Neurocords LLCs assets related to regenerative medicine therapies for spinal cord injuries. This strategic acquisition aims to expand access to cost-effective treatments by integrating Neurocords technology with Orgenesiss decentralized cell processing approach. The acquisition involves an equity transaction, with Orgenesis issuing 1,200,000 shares of common stock to Neurocords. Orgenesis plans to leverage its AI-based technology to enhance the production of autologous stem cells, potentially accelerating the development of transformative therapies for spinal cord injuries. The acquisition aligns with Orgenesiss mission to improve healthcare outcomes through innovative cell and gene therapies.